Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma.

Vaishampayan, Ulka N; Heilbrun, Lance K; Marsack, Cynthia; Smith, Daryn W; Flaherty, Lawrence E

Vaishampayan, Ulka N; Heilbrun, Lance K; Marsack, Cynthia; Smith, Daryn W; Flaherty, Lawrence E.

Affiliation

Vaishampayan UN; Division of Oncology, Department of Medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA. vaishamu@karmanos.org

Anticancer Drugs ; 18(10): 1221-6, 2007 Nov.

Article in En | MEDLINE | ID: mdl-17893524

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Melanoma/drug therapy; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Female; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha/administration & dosage; Male; Melanoma/secondary; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Thalidomide/administration & dosage

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Melanoma Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Anticancer Drugs Journal subject: ANTINEOPLASICOS Year: 2007 Document type: Article Affiliation country: United States Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links